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ABSTRACT
Objectives: To investigate the cost-effectiveness of a
telehealth intervention for primary care patients with
raised cardiovascular disease (CVD) risk.
Design: A prospective within-trial patient-level
economic evaluation conducted alongside a
randomised controlled trial.
Setting: Patients recruited through primary care, and
intervention delivered via telehealth service.
Participants: Adults with a 10-year CVD risk ≥20%,
as measured by the QRISK2 algorithm, with at least 1
modifiable risk factor.
Intervention: A series of up to 13 scripted, theory-led
telehealth encounters with healthcare advisors, who
supported participants to make behaviour change, use
online resources, optimise medication and improve
adherence. Participants in the control arm received
usual care.
Primary and secondary outcome measures:
Cost-effectiveness measured by net monetary benefit at
the end of 12 months of follow-up, calculated from
incremental cost and incremental quality-adjusted life
years (QALYs). Productivity impacts, participant out-of-
pocket expenditure and the clinical outcome were
presented in a cost-consequences framework.
Results: 641 participants were randomised—325 to
receive the telehealth intervention in addition to usual
care and 316 to receive only usual care. 18% of
participants had missing data on either costs, utilities
or both. Multiple imputation was used for the base
case results. The intervention was associated with
incremental mean per-patient National Health Service
(NHS) costs of £138 (95% CI 66 to 211) and an
incremental QALY gain of 0.012 (95% CI −0.001 to
0.026). The incremental cost-effectiveness ratio was
£10 859. Net monetary benefit at a cost-effectiveness
threshold of £20 000 per QALY was £116 (95% CI
−58 to 291), and the probability that the intervention
was cost-effective at this threshold value was 0.77.
Similar results were obtained from a complete case
analysis.
Conclusions: There is evidence to suggest that the
Healthlines telehealth intervention was likely to be cost-
effective at a threshold of £20 000 per QALY.
Trial registration number: ISRCTN27508731;
Results. Prospectively registered 05 July 2012.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
cause of death worldwide.1 Many of these
deaths could be avoided by addressing modiﬁ-
able behavioural risk factors such as smoking,
diet and exercise.1–4 Costs associated with CVD
are substantial,5 6 and predicted to increase.7 8
There is an urgent need to identify cost-
effective healthcare interventions that can
effect behavioural changes, address the
burden of CVD, and efﬁciently and effectively
support patient care. The Healthlines study
was a multicentre, parallel two-arm and indi-
vidually randomised controlled trial (RCT)
designed to assess the effectiveness and cost-
effectiveness of a telehealth intervention for
primary care patients. The intervention was
Strengths and limitations of this study
▪ We report a within-trial economic evaluation of
the one of the largest randomised controlled
trials designed to evaluate a telehealth-based
complex intervention for the management of car-
diovascular disease risk.
▪ This prospective economic evaluation used
detailed patient-level data to contribute to the
small body of evidence concerned with the cost-
effectiveness of telehealth for patients with long-
term conditions.
▪ The intervention was likely to be cost-effective
when adopting a UK health system perspective, a
conclusion that held whether complete case or
imputed data were analysed.
▪ The recruitment rate to the trial was relatively
low, and this may affect the generalisability of
these findings.
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intended to promote behaviour change, optimisation of
medication, improved coordination of care and improved
medication adherence in patients with a high risk of devel-
oping CVD. Development of the intervention,9 the proto-
col for the trial10 and the main results of the trial have
been published elsewhere.11
Evidence of the effectiveness and cost-effectiveness of
telehealth in general,12 and for the management of
patients with elevated CVD risk,13 is mixed. In this
paper, we report the results of an economic evaluation
conducted alongside the Healthlines RCT. We estimated
the cost-effectiveness of the telehealth service from a
National Health Service (NHS) perspective for primary
care patients with elevated CVD risk. A companion
paper14 complements the within-trial evaluation pre-
sented in this paper with simulation modelling of the
cost-effectiveness of this intervention over the remaining
lifetime of trial participants.
METHODS
RCT setting and participants
Participants aged between 40 and 74 on the date of invita-
tion were recruited from 42 general practices in or near
Bristol, Shefﬁeld and Southampton. Participants were
individuals with a 10-year risk of a cardiovascular event of
≥20% calculated using the QRISK2 algorithm,15 and with
at least one of the following modiﬁable CVD risk factors:
(1) systolic blood pressure ≥140 mmHg, (2) body mass
index (BMI) ≥30 kg/m2 and/or (3) a current smoker.
Individuals were excluded from the trial if they had a
conﬁrmed diagnosis of CVD (deﬁned as history of heart
attack, angina, heart failure, stroke or transient ischae-
mic attack), currently or planning to be pregnant, or
unable to communicate verbally in English. In total, 641
participants were randomised on a 1:1 basis to receive
either the telehealth intervention in addition to usual
care or usual care alone for up to 12 months.
An NHS perspective was adopted for the cost-
effectiveness analysis, which compared NHS costs with
quality-adjusted life years (QALYs) over the 12 months
of trial follow-up. Self-reported data on personal expend-
iture and productivity impacts were also collected and
are presented as part of a cost-consequences analysis.
Intervention
A structured programme of work (C Salisbury,
A O’Cathain, C Thomas, et al. Telehealth for patients with
long-term health conditions: development and evaluation
of the Healthlines Service. NIHR Journals Library—
Programme Grants for Applied Research, Under review)
was used to develop the de novo, theory-driven, web and
phone-based telehealth service received by participants in
the intervention arm. The core feature of the Healthlines
Service consisted of scripted telephone support and
responsive advice delivered by NHS Direct Health
Information Advisors (HIAs). The scripts used in the tele-
phone encounters, based on a successful US
intervention,16 17 focused on goal setting, stimulus control
and problem solving to address modiﬁable risk factors for
CVD. These encounters were responsive to need, and par-
ticipants could, for example, request calls with supervisors,
and could ask to be directed to sources of information
relevant to the management of their condition.
Participants were eligible to receive up to 13 scheduled
telephone encounters delivered approximately every
4 weeks over the course of the 12 months of trial follow-up.
The intervention was in addition to usual care.
Participants with systolic blood pressure ≥140 mmHg
and without atrial ﬁbrillation were offered a home blood
pressure monitor. Blood pressure was reviewed during
each encounter with the Healthlines advisor and targets
were set based on guidelines issued by the National
Institute for Health and Care Excellence (NICE).18
General practitioners were advised if patients were not
adherent to medication. Participants in the intervention
arm were provided with access to an online web portal
containing summaries of progress (such as graphs of
blood pressure against target), and access to online
resources relevant to the management of their condition.
Participants in the control arm received unmodiﬁed
usual care.
Measurement and valuation of outcomes
The primary outcome of the RCT was the proportion of
participants responding to treatment, deﬁned as a
binary outcome reﬂecting maintenance or reduction of
10-year CVD risk estimated using the QRISK2 algorithm
at 12 months after randomisation. QRISK2 scores at
12 months were calculated by updating age and modiﬁ-
able risk factors, with all other variables held constant.
Participants responded to questions concerning
health-related quality of life at baseline and at 6 and
12 months postrandomisation using the EQ-5D-5L
measure.19 This generic instrument measures ﬁve
dimensions (mobility, self-care, usual activities, pain and
discomfort) of health-related quality of life, and uses ﬁve
categories to characterise health states associated with
these dimensions: no problems, slight problems, moder-
ate problems, severe problems and extreme problems.
The EQ-5D-5L UK valuations were not available to us at
the time of trial analysis, and hence the EQ-5D-5L
responses were ‘cross-walked’ to the three-level version
of the instrument (EQ-5D-3L) and valued using the
Euroqol value set for the UK.20
Measurement and valuation of resource use
Relevant primary care consultations and information on
prescriptions related to CVD risk (lipid regulating, antihy-
pertensives, antiplatelet, obesity treatments and nicotine
dependence medication) were collected (with consent)
from medical records. Primary care consultations were
costed using Curtis.21 Prescribed medications were costed
using the Prescription Cost Analysis England (PCAE)
database,22 and checked against the British National
Formulary.23
2 Dixon P, et al. BMJ Open 2016;6:e012352. doi:10.1136/bmjopen-2016-012352
Open Access
Questionnaires issued to participants at 6 and
12 months were used to collect information on health-
care use associated with CVD risk not available from
primary care records. Examples of these resources
include hospital and ambulance use, district nurse con-
sultations, and use of NHS walk-in centres. Since we
imputed costs rather than resource use per se for our
base case analysis, we present resource use for available
and complete cases in the online supplementary
material rather than in the main text.
The sources used to value these resources uses were
primarily Curtis,21 NHS National Reference Costs for
2012/201324 and other sources as described in the
online supplementary tables A1 and A2. Participants
also reported use of private health services (eg, private
nutritionists), and out-of-pocket expenditure (eg, self-
help books) associated with CVD risk. Participants
reported time absent from work due to CVD risk, which
was valued, where appropriate, at the national median
gross hourly wage for 2013 of £11.59.25
The estimated cost of the intervention was based on
the number and length of telephone calls, the number
of failed attempts made by HIAs to contact participants,
blood pressure monitors and the costs associated with
establishing the service, such as training costs. Unit costs
for these resources are described in the online supple-
mentary table A3.
HIAs worked 40 hours per week, and were remuner-
ated at band 4 of the NHS ‘Agenda for Change’ pay
scale. Salaries and associated costs (such as overhead)
were based on Curtis.21 The cost per hour of participant
contact time was estimated based on a ratio of contact to
non-contact time calculated from task-scheduling
diaries. Initial and ongoing training of HIAs was pro-
vided by a nurse-grade trainer; the training was assumed
to last for 3 years and costs were amortised on that basis.
This assumes that training of this type would not be
redundant after 1 year; instead, it assumes that the train-
ing would be effective for 3 years, after which additional
training might become necessary.
Costs are reported in 2012/2013 pounds sterling.
Analysis of data
Summary statistics were estimated for all variables used
in the economic analysis, and any missingness was identi-
ﬁed. All cost-effectiveness analysis was conducted on an
‘intention-to-treat’ basis. Neither costs nor beneﬁts were
discounted given the follow-up period of the trial.
A very small proportion of patients (<0.5%) had
missing data on primary care consultations. This was pri-
marily due to patients having moved during the study to
different practices. Mean values were imputed for these
patients. Complete cases refer to cases constructed after
initial data cleaning and mean imputation of the small
amount of missing primary care consultation data.
These complete cases had no other missing cost or
EQ-5D-5L data needed to undertake inferential cost-
effectiveness analysis from the perspective of the NHS.
Approximately 82% of participants were categorised as
complete cases under this deﬁnition.
Multiple imputation was used for all other missing
data. Aggregate costs at the level of primary care, medi-
cation, other NHS costs and responses to the EQ-5D-5L
at each time point were imputed using the—ice—
command26 27 in Stata V.13.1, which implements mul-
tiple imputation by chained equations.
The imputation model included demographic, cost
and clinical outcome variables at baseline and follow-up,
stratiﬁed by trial arm. Predictive mean matching27 was
applied to account for non-Gaussian distributions of
some included variables, and passive imputation was
used for those categorical variables that were functions
of other included variables.
The number of imputations (n=60) was selected to be
greater than the proportion of missing data (18%).27 We
followed the approach set out in Faria et al28 in order to
implement ‘Rubin’s rules’, so that variation within and
between the set of 60 imputed data sets was reﬂected in
the analysis of cost-effectiveness.
Health-related quality of life utilities were measured at
baseline, and 6 and 12 months using responses to
EQ-5D-5L questionnaires. QALYs were calculated from
these responses using the ‘area under the curve’
method,29 and were adjusted for baseline differences in
EQ-5D-5L scores.30
The cost-effectiveness analysis used seemingly unre-
lated regression (SUR), for which we rely on the near
normality of differences in sample means and differ-
ences in sample variances in large samples.31 32 We
implemented SUR using the—sureg—command in
Stata. We regressed costs and QALYs on a binary variable
indicating allocation to trial arm. For the QALY equa-
tion, we also included controlled for baseline imbal-
ances in utility.30 No other covariates were included in
these regressions.
Incremental cost-effectiveness ratios (ICERs), cost-
effectiveness acceptability curves (CEACs), net monetary
beneﬁt estimates33 and CIs around net monetary beneﬁt
point estimates were calculated parametrically from
regression output. Net monetary beneﬁt was estimated
at the NHS threshold values suggested by NICE of
£20 000–£30 000 per QALY.34
The cost-consequences analysis used all available
cases, which were identiﬁed on a variable-by-variable
basis. These were deﬁned as having complete data across
all relevant time points for any individual variable.
Stata V.13.1 software (Statacorp: College Station, Texas,
USA) was used in all analyses.
Sensitivity analysis
We carried out sensitivity analyses in two areas of uncer-
tainty to test the robustness of our results. First, com-
plete case analysis was conducted as a check on the base
case imputed cost-effectiveness analysis. Second, the
base case (imputed) results were assessed for their sensi-
tivity to self-reported use of secondary care in order to
Dixon P, et al. BMJ Open 2016;6:e012352. doi:10.1136/bmjopen-2016-012352 3
Open Access
assess the effect of rare but expensive events and to
address potential recall bias or misclassiﬁcation of
resource use.
RESULTS
The trial recruited a total of 641 participants: 325 were
randomised to receive the intervention and 316 received
usual care in the control arm. The mean age of partici-
pants in the trial was 67.2 years, of whom 80% were male,
and 99% of all participants were of white ethnicity. Mean
QRISK2 score at baseline in the usual care arm was 30.8
(SD 9.5), and 31.1 (SD 10.2) in the intervention arm.
Compliance with the intervention was reasonably high;
8% of participants received two or fewer encounters with
the HIAs (including the initial introductory encounter),
60% received 3–11 encounters and 32% received 12–13
encounters. The median number of encounters received
was 10 (IQR 8–12). Two participants had missing data on
the number of encounters received.
Outcomes
There was an imbalance in the baseline imputed
EQ-5D-5L scores between the two groups (0.77 (SE
0.01) in the control group vs 0.80 (SE 0.1) in the inter-
vention group). Once this was adjusted for the size of
the QALY gain was 0.012 in the imputed data set used
for the base case analysis (table 1). Response to treat-
ment, measured as the maintenance or reduction of
QRISK2 scores, was modestly higher in the intervention
arm (adjusted OR 1.3, 95% CI 1.0 to 1.9).
Resource use and cost
The mean cost per participant of providing the interven-
tion was estimated to be £129 (SD £56.33), of which the
cost of the encounter calls constituted 85% of total cost
(table 2). NHS costs (primary care consultations, medi-
cation costs, use of NHS community services and NHS
secondary care) were similar in each arm (table 3).
Online supplementary tables A4–A10 provide disaggre-
gated data on resource use and costs for available and
complete cases (as deﬁned above).
Cost-consequences
Table 4 presents a cost-consequences matrix showing
costs from different perspectives and a range of
outcomes.
Costs to the NHS were higher in the intervention arm,
largely due to the cost of the intervention. The societal
value of lost production was slightly higher per patient
in the control arm, but not signiﬁcantly so. The com-
parison is affected by the low numbers of participants
reporting employment at either 6 or 12 months
(25.2%), and the number of employed participants
reporting no impact (95.1%) of CVD risk factors on
their employment. Participants randomised to usual care
reported higher mean per patient private healthcare
costs than in the intervention arm in available cases, but
lower out-of-pocket expenditure than intervention
participants.
These costs were associated with a marginal increase
in the proportion of responders (deﬁned in the pub-
lished trial protocol as the maintenance or reduction of
10-year cardiovascular risk estimated on the basis of the
QRISK2 score after 12 months) in the intervention arm,
with improvements in EQ-5D-5L utility at the end of
12 months of follow-up, and with a small QALY
improvement.
There was a marginal increase in response to treat-
ment (as deﬁned above) in the treatment arm. The
intervention was also associated with reductions in blood
pressure (mean difference in systolic pressure
−2.7 mm Hg; 95% CI −4.7 to −0.6) and in weight
(−1.0 kg; 95% CI −1.8 to −0.3). Improvements in diet,
physical activity, medication to care and satisfaction with
treatment for participants randomised to the interven-
tion arm were also observed. The intervention did not
improve cholesterol or smoking status.
Cost-effectiveness
Cost-effectiveness results from an NHS perspective are
presented in table 5. The ICER is £10 859 and there is a
probability of 0.77 that the intervention is cost-effective
at a threshold value of £20 000 per QALY. The probabi-
lity that the intervention is cost-effective at other values
of the cost-effectiveness threshold is shown in ﬁgure 1.
The between-arm QALY difference of 0.012 corresponds
to ∼4 additional days in ‘perfect’ health over the course
of a year for participants randomised to the intervention
arm rather than to the control arm.
Table 1 Imputed QALYs
Cost and outcomes
Usual care
(n=316*)
mean (SE)
Intervention
(n=325*)
mean (SE)
Imputed unadjusted QALYs 0.774 (0.100) 0.810 (0.009)
Imputed QALYs, adjusted
for baseline imbalance
0.786 (0.005) 0.798 (0.005)
*This sample size is based on 60 imputed data sets.
QALYs, quality-adjusted life years; SE, standard error.
Table 2 Mean (SD) intervention cost (£) per participant
for all participants and complete cases
Intervention
elements
All participants
(n=325) mean £
(SD)
Complete cases
(n=262) mean £
(SD)
Encounter calls 108.80 (49.75) 114.68 (46.07)
Non-scheduled calls 1.39 (2.57) 1.47 (2.65)
All calls 110.20 (50.13) 116.15 (46.24)
Blood pressure
monitor
18.92 (18.78) 18.89 (18.79)
Total cost per
participant
129.12 (56.33) 135.04 (53.02)
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Sensitivity analyses
The base case results are insensitive to the exclusion of
secondary NHS costs. The effect of removing these costs
is to slightly narrow cost differences between arms (rela-
tive to the base case) so that the ICER reduces to
£10 003, and hence these costs do not have a material
impact on the likely cost-effectiveness of the intervention.
Table 6 presents the results of a complete case analysis
of cost-effectiveness from an NHS perspective. The
CEAC associated with these results is presented as online
Table 4 Cost-consequence matrix
Cost and outcomes
Usual
care N Intervention N Difference (95% CI)
Available data on costs (£)
Mean cost of intervention 0 316 129 325 –
Mean cost of NHS resources,
excluding intervention costs
361 283 362 285 1 (−72 to 76)*
Mean cost of NHS resources,
including intervention costs
361 283 494 283 132 (57 to 212)*
Out-of-pocket expenses 64 298 79 299 15 (−20 to 50)*
Private healthcare 110 298 59 299 −50 (−141 to 1)*
Mean societal value per patient of lost production 76 298 52 299 −24 (−133 to 54)*
Consequences†
QRISK2 response to treatment (proportion of
responders)
43% 291 50% 295 Adjusted OR 1.3 (1.0 to 1.9)
EQ-5D-5L at 12 months, unadjusted for baseline‡ 0.776 297 0.812 295 0.037 (0.007 to 0.070)*
QALYs, adjusted for baseline‡ 0.788 279 0.799 275 0.01 (−0.014 to 0.040)*
*CI calculated as accelerated and bias corrected interval from 1000 bootstrap replicates to account for skewed distributions.
†All consequences measured at 12 months, or over a period of 12 months.
‡Based on available data.
NHS, National Health Service; QALYs, quality-adjusted life years.
Table 5 Cost-effectiveness of the intervention from an NHS perspective
Cost of services Usual care mean Intervention mean Incremental difference (95% CI)
Costs and QALYs
Total NHS costs £364 £502 £138 (66 to 211)
Adjusted QALYs 0.786 0.798 0.012 (−0.001 to 0.026)
Cost-effectiveness statistics
ICER: £10 859
Probability that intervention cost-effective at CE threshold of £20 000: 0.77
Probability that intervention cost-effective at CE threshold of £30 000: 0.87
NMB at threshold of £20 000 (95% CI): £116 (105 to 128)
CE, cost-effectiveness; ICER, incremental cost-effectiveness ratio; NHS, National Health Service; NMB, net monetary benefit; QALYs,
quality-adjusted life years.
Table 3 Imputed NHS costs
Cost and outcomes N*
Usual care mean £
(standard error)†
Intervention mean £
(standard error)†
Imputed hospital, ambulance and other mean NHS costs 641 56 (19) 65 (22)
Imputed mean drug costs 641 67 (8) 67 (6)
Imputed mean primary care costs 641 241 (11) 242 (9)
Imputed mean NHS costs, excluding cost of the intervention 641 364 (26) 373 (26)
Imputed mean intervention costs 641 – 129 (3)
Imputed mean NHS-related costs, including cost of the
intervention
641 364 (26) 502 (27)
*This sample size is based on 60 imputed datasets.
†Standard errors are reported for imputed data, rather standard deviations.
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supplementary ﬁgure A1. The complete case results are
similar to those of the imputed base case results.
DISCUSSION
We conducted a within-trial evaluation of cost-
effectiveness of a de novo telehealth intervention in
patients with elevated CVD risk. Trial participants in the
control arm received usual care. Participants were fol-
lowed up for 12 months. Resource use data were col-
lected at 6 and 12 months, and information on
health-related quality of life was measured using
responses to the EQ-5D-5L questionnaire. Using a
health system perspective, we compared healthcare costs
to QALYs in the base case cost-effectiveness analysis.
The between-arm difference in QALYs is modest. This
small improvement in QALYs in the intervention arm
may reﬂect the indirect impact of engaging with and
being supported by the HIAs. For example, intervention
participants reported greater medication adherence,
better access to support and satisfaction with treatment
than did control participants (C Salisbury, A O’Cathain,
C Thomas, et al. Under review). Intervention partici-
pants reported small improvements in blood pressure
and BMI, but not with respect to smoking or cholesterol
(C Salisbury, A O’Cathain, C Thomas, et al. Under
review). The balance of these impacts—on the sense of
being supported, greater satisfaction with treatment and
some improvements in ‘hard’ health indicators such as
weight—may have contributed to EQ-5D-5L responses
that favoured the intervention.
Strengths
The Healthlines trial was one of the largest RCTs
designed to evaluate a telehealth-based complex inter-
vention for the management of CVD risk. The interven-
tion was based on a programme of work (C Salisbury,
A O’Cathain, C Thomas, et al. Under review) intended
to establish the acceptability of telehealth to patients
with chronic conditions, and to support the develop-
ment of an evidence-based, responsive telehealth service
for evaluation in the context of a pragmatic trial design.
This economic evaluation contributes to the small body
of evidence concerned with the cost-effectiveness of tele-
health for patients with long-term conditions.
The economic evaluation was conducted alongside
the trial, and prospectively collected detailed patient-
level data. The analysis was conducted in line with best
practice guidance.35 The amount of missing data in the
cost and quality of life variables necessary to conduct
inferential cost-effectiveness analysis was similar in each
arm. Imputed and complete case cost-effectiveness
results were similar.
Adherence to the intervention was relatively strong,
with a median of 10 out of 13 scheduled encounters
received. This suggests that patients randomised to the
intervention were willing to engage with the Healthlines
Service.
Limitations
The economic evaluation did not seek to measure the
scalability of the intervention to larger (eg, national)
patient groups, although the intervention was speciﬁ-
cally designed to be easily scaled-up. It is conceivable
that scale economies (eg, training more HIAs at the
same cost) and other savings (eg, through very large
bulk purchases of blood pressure monitors) could be
Figure 1 Cost-effectiveness acceptability curve from an
NHS perspective for imputed model. NHS, National Health
Service; QALY, quality-adjusted life year.
Table 6 Sensitivity analysis: cost-effectiveness complete case from an NHS perspective
Cost of services Usual care (n=266) mean Intervention (n=262) mean
Incremental difference
(95% CI)
Costs and QALYs
Total NHS costs—complete case £367 £490 £124 (42 to 206)
QALYs—complete case 0.788 0.800 0.011 (−0.001 to 0.025)
Cost-effectiveness statistics
ICER: £10 366
Probability that intervention cost-effective at CE threshold of £20 000: 0.79
Probability that intervention cost-effective at CE threshold of £30 000: 0.87
NMB at threshold of 20 000 (95% CI): £115 (103 to 127)
CE, cost-effectiveness; ICER, incremental cost-effectiveness ratio; NHS, National Health Service; NMB, net monetary benefit; QALYs,
quality-adjusted life years.
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realised to reduce overall intervention cost. There was
no evidence from the trial that substantial efﬁciencies
could have been secured but were left unexploited. A
related limitation is that the recruitment rate of the trial
was relatively low.11 This will affect the generalisability of
the ﬁndings, although it is unclear whether low reluc-
tance is due to lack of interest in telehealth or unwilling-
ness to participate in research.
The 12-month follow-up period of the trial means that
questions concerning long-term outcomes cannot be
answered deﬁnitively, and nor can the issue of whether
time-limited (eg, for 12 months) or ongoing (eg, until
QRISK2 score was reduced to some target level) tele-
health support would be most cost-effective. The inter-
vention may affect the health of participants beyond the
end of follow-up for at least two reasons: any improve-
ments in habits and self-management are maintained,
and the reduced QRISK2 scores in the intervention
during trial follow-up will (slightly) reduce the likeli-
hood of future CVD events occurring. A companion
paper14 describes the results of a simulation intended to
assess the cost-effectiveness of the intervention from a
lifetime perspective.
Other literature
Incremental costs per patient in the intervention arm
were £138. There was a small QALY difference
between arms of 0.012. We note that Bergmo’s36
review of QALY gains in telehealth interventions
found that 17 included studies reported small, posi-
tive effects on quality of life. This is consistent with
the results reported here. Overall, the intervention is
likely to be cost-effective at conventional NHS cost-
effectiveness thresholds.
Comparison of the ﬁndings of this economic evalu-
ation with other literature is complicated by differences
between studies in technologies assessed, the types of
condition analysed, study design and patient population.
Evidence for the cost-effectiveness of telehealth in
general is mixed,36–39 and has been described as being
of low quality in some cases.36 40–42
A notable example of cost-effectiveness analysis
within an English NHS context of telehealth for long-
term conditions was evaluation of the ‘Whole Systems
Demonstrator’ (WSD) project.43 44 Patients with a
long-term condition (heart failure, chronic obstructive
pulmonary disease or diabetes) received either tele-
health (n=845) or usual care (n=728) for 12 months
following cluster randomisation of practices in three
study sites.
The WSD intervention comprised the use of a broad
class of telehealth and telemonitoring equipment, which
differed by study site. Participants were asked to take
readings using this equipment at the same time each
day up to 5 days per week. Specialist nurses monitored
and responded to information from patients.
The adjusted estimated QALY gain after 12 months in
the WSD study was 0.012 in favour of the
intervention, the same mean difference reported here
for Healthlines, despite the differences in technology,
patient characteristics and study design. NHS and social
care costs were substantially higher than in Healthlines,
with WSD intervention arm costs £1110 higher than in
the control arm. The costs of the intervention itself were
estimated to be substantially higher than in Healthlines
(£1847 average annual cost for those with equipment
and reporting costs at 12-month follow-up in WSD, com-
pared with £129 in Healthlines), although other costs
were lower in the intervention arm. The estimated WSD
ICER was £92 000.
This high-level comparison between the cost-
effectiveness results of the Healthlines trial and from the
WSD trial indicate the sensitivity of the cost-effectiveness
results to the type and costs of technology evaluated.
Despite the same mean QALY difference, the WSD
evaluation suggested that substantial changes in inter-
vention cost would be necessary before the service could
be considered as a cost-effective means of managing
patients with long-term conditions. In contrast to the
WSD, the Healthlines intervention was designed to
support self-management of chronic diseases at low cost,
using readily available low-cost technology such as
accessible websites, and telephone support from staff
without clinical training.
These considerations are relevant to future study
design in this area. Continuing evolution in technology
and technology cost is likely to inﬂuence both the effect-
iveness and cost-effectiveness of new interventions.
CONCLUSION
The Healthlines RCT provided weak evidence of a
modest effect on 10-year CVD risk of the telehealth
intervention on the primary binary outcome of
response to treatment. However, the intervention was
estimated to be cost-effective (measured as a function
of the ratio of incremental costs to incremental
QALYs) from an NHS perspective after 12 months of
trial follow-up.
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